These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 6096286)

  • 1. Bisantrene solubility and skin toxicity studies: efficacy of sodium bicarbonate as a local ulceration antidote.
    Dorr RT; Peng YM; Alberts DS
    Invest New Drugs; 1984; 2(4):351-7. PubMed ID: 6096286
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The limited role of corticosteroids in ameliorating experimental doxorubicin skin toxicity in the mouse.
    Dorr RT; Alberts DS; Chen HS
    Cancer Chemother Pharmacol; 1980; 5(1):17-20. PubMed ID: 7460191
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II evaluation of bisantrene hydrochloride in refractory malignant melanoma. A Southwest Oncology Group Study.
    Alberts DS; Mason-Liddil N; Green SJ; Cowan JD; Fletcher WS; Neilan B; Guy JT; Epstein RB
    Invest New Drugs; 1987; 5(3):289-92. PubMed ID: 3667164
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized trial of doxorubicin, bisantrene, and mitoxantrone in advanced breast cancer: a Southwest Oncology Group study.
    Cowan JD; Neidhart J; McClure S; Coltman CA; Gumbart C; Martino S; Hutchins LF; Stephens RL; Vaughan CB; Osborne CK
    J Natl Cancer Inst; 1991 Aug; 83(15):1077-84. PubMed ID: 1875415
    [TBL] [Abstract][Full Text] [Related]  

  • 5. N-phosphoryl derivatives of bisantrene. Antitumor prodrugs with enhanced solubility and reduced potential for toxicity.
    Murdock KC; Lee VJ; Citarella RV; Durr FE; Nicolau G; Kohlbrenner M
    J Med Chem; 1993 Jul; 36(15):2098-101. PubMed ID: 8340913
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I clinical investigation of 9,10-anthracenedicarboxaldehyde bis[(4,5-dihydro-1H-imidazol-2-yl)hydrazone] dihydrochloride with correlative in vitro human tumor clonogenic assay.
    Alberts DS; Mackel C; Pocelinko R; Salmon SE
    Cancer Res; 1982 Mar; 42(3):1170-5. PubMed ID: 7037174
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I and pharmacokinetic comparison of hepatic arterial and peripheral vein infusions of bisantrene for liver cancer.
    Weiss GR; Hersh M; Kuhn JG; Ludden TM; von Hoff DD; Kisner DL; Pirtle TE
    Cancer Chemother Pharmacol; 1985; 15(2):144-8. PubMed ID: 4017163
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Experimental studies and phase II trial of bisantrene in advanced urothelial malignancies.
    Scher HI; Ahmed T; Yagoda A; Kyriazis AP; Watson RC
    Cancer Invest; 1985; 3(2):123-7. PubMed ID: 3995377
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bisantrene, an active drug in patients with advanced breast cancer.
    Osborne CK; Von Hoff DD; Cowan JD; Sandbach J
    Cancer Treat Rep; 1984 Feb; 68(2):357-60. PubMed ID: 6697324
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II trial of bisantrene in patients with intermediate and high grade diffuse non-Hodgkin's lymphomas.
    Miller TP; Jones SE; Alberts DS; Mackel C
    Invest New Drugs; 1984; 2(1):75-7. PubMed ID: 6469502
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disposition of bisantrene in humans and rabbits: evidence for intravascular deposition of drug as a cause of phlebitis.
    Powis G; Kovach JS
    Cancer Res; 1983 Feb; 43(2):925-9. PubMed ID: 6848203
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Retroviral transfer of the human MDR1 gene confers resistance to bisantrene-specific hematotoxicity.
    Aksentijevich I; Cardarelli CO; Pastan I; Gottesman MM
    Clin Cancer Res; 1996 Jun; 2(6):973-80. PubMed ID: 9816258
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of sodium thiosulfate as a local antidote to mechlorethamine skin toxicity in the mouse.
    Dorr RT; Soble M; Alberts DS
    Cancer Chemother Pharmacol; 1988; 22(4):299-302. PubMed ID: 3168143
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activation of tumor-cytostatic macrophages with the antitumor agent 9,10-anthracenedicarboxaldehyde bis[(4,5-dihydro-1H-imidazole-2-yl)hydrazone] dihydrochloride (bisantrene).
    Wang BS; Lumanglas AL; Ruszala-Mallon VM; Durr FE
    Cancer Res; 1984 Jun; 44(6):2363-7. PubMed ID: 6426780
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I study of bisantrene in acute nonlymphoblastic leukemia.
    Marty M; Ferme C; Gisselbrecht C; Guy H; Clark MJ; Bancillon A; Boiron M
    Cancer Treat Rep; 1985 Jun; 69(6):703-5. PubMed ID: 4016773
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stability of amrinone and digoxin, procainamide hydrochloride, propranolol hydrochloride, sodium bicarbonate, potassium chloride, or verapamil hydrochloride in intravenous admixtures.
    Riley CM; Junkin P
    Am J Hosp Pharm; 1991 Jun; 48(6):1245-52. PubMed ID: 1650135
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vinca alkaloid skin toxicity: antidote and drug disposition studies in the mouse.
    Dorr RT; Alberts DS
    J Natl Cancer Inst; 1985 Jan; 74(1):113-20. PubMed ID: 3855472
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo and in vitro metabolism of the new anticancer drug bisantrene.
    Peng YM; Alberts DS; Davis TP
    Cancer Chemother Pharmacol; 1985; 14(1):15-20. PubMed ID: 3965156
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II evaluation of bisantrene in patients with advanced non-small cell lung carcinoma.
    Feld R; Evans WK; Shepherd FA; Deboer G; Ottema B
    Cancer Treat Rep; 1985 Feb; 69(2):209-10. PubMed ID: 3971392
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Depression of cardiac function by bisantrene.
    Artman M; Roloff JS; Olson RD; Parrish MD
    South Med J; 1985 Dec; 78(12):1517-8. PubMed ID: 3865379
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.